Literature DB >> 8573185

Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A.

R F Omar1, H V Gelboin, A D Rahimtula.   

Abstract

Liver microsomes from rats treated with various P450 inducers were examined for their ability to metabolize the mycotoxin ochratoxin A (OTA) to 4(R)-4-hydroxyochratoxin A (4R), the major metabolite, and 4(S)-4-hydroxyochratoxin A (4S), the minor metabolite. Pretreatment of rats with phenobarbital (PB), dexamethasone (DXM), 3-methylcolcanthrene (3MC) and isosafrole (ISF) greatly induced 4R formation. PB, DXM, 3MC, clofibrate (CLF) and ISF treatments also induced 4S formation. Isoniazid (INH) pretreatment primarily induced 4S formation. The pH optimum for 4R formation was found to be 6.0 with 3MC microsomes, and 6.5 with PB and DXM microsomes. For 4S formation, the pH optimum was 7.0. At the optimum pH (compared with pH 7.4), 4R formation increased 40-50% with PB and DXM microsomes but 8.0-fold with 3MC microsomes. Studies using the inhibitors metyrapone and alpha-naphthoflavone as well as monoclonal antibodies against various P450s suggested that at least the P450 isoforms IA1/IA2, IIB1 and IIIA1/IIIA2 are involved in 4R formation. Using urinary excretion of the enzymes alkaline phosphatase and gamma-glutamyl transferase as an index of renal damage, we observed that pretreatment of rats with PB, which induced hepatic P450 (P450II2B1), protected against OTA nephrotoxicity, whereas cobalt-protoporphyrin IX pretreatment, which decreased P450 levels, exacerbated OTA nephrotoxicity. Our results suggest that at least P450IIB1-dependent metabolism of OTA leads to its detoxication and that OTA itself may be toxic in some circumstances or that other pathways are responsible for its activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573185     DOI: 10.1016/0006-2952(95)02194-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

Review 1.  A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis.

Authors:  Janette H Hope; Bradley E Hope
Journal:  J Environ Public Health       Date:  2011-12-29

2.  Mutagenicity of ochratoxin A and its hydroquinone metabolite in the SupF gene of the mutation reporter plasmid Ps189.

Authors:  Steven A Akman; Marissa Adams; Doug Case; Gyungse Park; Richard A Manderville
Journal:  Toxins (Basel)       Date:  2012-04-16       Impact factor: 4.546

3.  Ochratoxin A-Induced Hepatotoxicity through Phase I and Phase II Reactions Regulated by AhR in Liver Cells.

Authors:  Hye Soo Shin; Hyun Jung Lee; Min Cheol Pyo; Dojin Ryu; Kwang-Won Lee
Journal:  Toxins (Basel)       Date:  2019-06-29       Impact factor: 4.546

Review 4.  Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level.

Authors:  Tamás Kőszegi; Miklós Poór
Journal:  Toxins (Basel)       Date:  2016-04-15       Impact factor: 4.546

5.  Protective Effect of Hydroxytyrosol Against Oxidative Stress Induced by the Ochratoxin in Kidney Cells: in vitro and in vivo Study.

Authors:  Rosalia Crupi; Ernesto Palma; Rosalba Siracusa; Roberta Fusco; Enrico Gugliandolo; Marika Cordaro; Daniela Impellizzeri; Carmen De Caro; Luigino Calzetta; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  Front Vet Sci       Date:  2020-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.